After falling roughly 46% from its all-time high, Tractor Supply has become one of retail's more intriguing turnaround candidates. CEO Hal Lawton recently invested more than $500,000 of his own money while institutions continue to own over 95% of the company. We examine whether today's valuation reset represents genuine opportunity—or simply reflects slowing fundamentals that still need to improve.

Read entire article

SiteOne Landscape Supply isn't flashy—but it may be one of the market's most overlooked industrial compounders. After a sharp correction, CEO Doug Black invested more than $816,000 of his own money while institutions continue to dominate the shareholder base. We examine the valuation, competitive moat, earnings, risks, and whether this roll-up story deserves another look.

Read entire article

Boston Scientific's stock has been cut nearly in half from its peak, yet the business remains fundamentally strong. With CEO Mike Mahoney buying $9 million worth of shares, a remarkably low 0.71 PEG ratio, billions in annual free cash flow, and overwhelming institutional ownership, is Wall Street overlooking one of healthcare's most attractive GARP opportunities?

Read entire article

CarMax isn't a flashy AI stock—but it may be one of the more interesting turnaround stories in today's market. New CEO Keith Barr just invested nearly $500,000 of his own money, institutions control over 112% of the float, and valuation appears unusually attractive on a PEG basis. Here's why we think investors should take a closer look.

Read entire article

Krispy Kreme shares remain down more than 80% from their highs, but insiders—including former 3G Capital executive Bernardo Hees—are buying aggressively. With free cash flow finally turning positive and margins improving, the iconic doughnut maker may be entering a new chapter.

Read entire article

Robinhood has evolved far beyond a commission-free trading app. With $307 billion in platform assets, 4.3 million Gold subscribers, and a $35 million insider purchase from fintech legend Meyer Malka, the company is increasingly positioning itself at the center of the next generation's financial lives.

Read entire article

Summit Therapeutics may be one of biotech's most fascinating high-risk, high-reward stories. Ivonescimab is taking aim at Keytruda, insiders keep buying shares, short interest remains elevated, and a major FDA decision looms in November 2026.

Read entire article

Norwegian Cruise Line Holdings may be more than a cruise recovery stock. With a new CEO, nearly $27 million in insider purchases, institutional ownership locking up almost the entire float, and valuation metrics that look surprisingly cheap, NCLH is turning into one of the more intriguing turnaround stories on deck.

Read entire article

Globant (NYSE: GLOB) may be one of the most intriguing AI-related value plays on the market. Trading 87% below its peak, the company combines a growing AI-native services platform, accelerating cash flow, aggressive share buybacks, institutional ownership above 100% of float, and a historic first insider purchase from former Hong Kong Exchange CEO Alejandro Aguzin. Is Wall Street missing the story?

Read entire article